Amarin Corp. PLC (NASDAQ:AMRN)’s share price rose 1.9% during mid-day trading on Thursday . The stock traded as high as $2.20 and last traded at $2.18, with a volume of 720,967 shares trading hands. The stock had previously closed at $2.14.

A number of equities research analysts have recently commented on AMRN shares. Jefferies Group reaffirmed a “buy” rating on shares of Amarin Corp. PLC in a report on Wednesday, June 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a report on Monday, May 9th. Finally, Zacks Investment Research raised shares of Amarin Corp. PLC from a “sell” rating to a “hold” rating in a report on Wednesday.

The stock’s market capitalization is $403.93 million. The stock has a 50-day moving average of $2.08 and a 200-day moving average of $1.71.

Amarin Corp. PLC (NASDAQ:AMRN) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.03. The company had revenue of $25.30 million for the quarter, compared to analysts’ expectations of $26.77 million. Amarin Corp. PLC’s revenue for the quarter was up 60.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.16) earnings per share. Equities analysts predict that Amarin Corp. PLC will post ($0.49) EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in AMRN. OppenheimerFunds Inc. increased its stake in Amarin Corp. PLC by 0.5% in the fourth quarter. OppenheimerFunds Inc. now owns 5,323,360 shares of the biopharmaceutical company’s stock valued at $10,061,000 after buying an additional 27,090 shares during the period. Tamarack Advisers LP purchased a new stake in Amarin Corp. PLC during the fourth quarter valued at about $10,395,000. Finally, Oracle Investment Management Inc. increased its stake in Amarin Corp. PLC by 9.4% in the fourth quarter. Oracle Investment Management Inc. now owns 6,645,793 shares of the biopharmaceutical company’s stock valued at $12,561,000 after buying an additional 568,915 shares during the period.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.